Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 2. J Am Acad Orthop Surg. 2009 Aug;17(8):515-27. doi: 10.5435/00124635-200908000-00005. Osteosarcoma. Messerschmitt PJ(1), Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ. Author information: (1)Department of Orthopaedic Surgery, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA. Osteosarcoma, the most common bone sarcoma, affects approximately 560 children and adolescents annually in the United States. The incidence of new diagnoses peaks in the second decade of life. Twenty percent of patients present with clinically detectable metastases, with micrometastases presumed to be present in many of the remaining patients. Treatment typically includes preoperative chemotherapy, surgical resection, and postoperative chemotherapy. Limb-salvage procedures with wide surgical margins are the mainstay of surgical intervention. Advances in chemotherapy protocols have led to a 5-year survival rate of 60% to 78%. Among the goals of future treatment regimens are improved chemotherapeutic agents with higher specificity and lower toxicity. DOI: 10.5435/00124635-200908000-00005